Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $180,691.89 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bioventures 2018 L.P. Mpm sold 25,131 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $7.19, for a total value of $180,691.89. Following the completion of the sale, the insider owned 4,177,215 shares in the company, valued at approximately $30,034,175.85. The trade was a 0.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Bioventures 2018 L.P. Mpm also recently made the following trade(s):

• On Thursday, September 3rd, Bioventures 2018 L.P. Mpm sold 32,263 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.17, for a total value of $231,325.71.
• On Tuesday, September 1st, Bioventures 2018 L.P. Mpm sold 29,088 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.06, for a total value of $205,361.28.
• On Monday, August 31st, Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.99, for a total value of $309,370.41.
• On Friday, August 28th, Bioventures 2018 L.P. Mpm sold 3,733 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.01, for a total value of $26,168.33.
• On Thursday, August 27th, Bioventures 2018 L.P. Mpm sold 38,922 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.20, for a total transaction of $280,238.40.

Entrada Therapeutics Stock Down 1.8%

Entrada Therapeutics stock traded down $0.13 during trading on Thursday, reaching $7.17. The stock had a trading volume of 395,559 shares, compared to its average volume of 255,201. Entrada Therapeutics, Inc. has a 52-week low of $5.02 and a 52-week high of $16.45. The stock has a market cap of $279.20 million, a PE ratio of -1.81 and a beta of -0.25. The business has a 50 day moving average price of $7.08 and a 200 day moving average price of $9.20.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The firm had revenue of $0.90 million during the quarter, compared to analyst estimates of $2.32 million. Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. On average, equities analysts predict that Entrada Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on TRDA shares. Roth Capital reissued a “buy” rating and issued a $11.00 target price on shares of Entrada Therapeutics in a report on Wednesday, August 12th. Weiss Ratings raised shares of Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Guggenheim lowered their price target on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Monday, June 8th. Finally, HC Wainwright downgraded Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 8th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.75.

Hedge Funds Weigh In On Entrada Therapeutics

Large investors have recently made changes to their positions in the stock. State of Wyoming purchased a new position in Entrada Therapeutics in the second quarter valued at about $37,000. Russell Investments Group Ltd. raised its holdings in Entrada Therapeutics by 72.7% during the third quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock worth $51,000 after purchasing an additional 3,707 shares during the last quarter. Occudo Quantitative Strategies LP acquired a new stake in Entrada Therapeutics in the second quarter valued at $68,000. Jain Global LLC purchased a new position in shares of Entrada Therapeutics in the third quarter valued at $69,000. Finally, IHT Wealth Management LLC acquired a new stake in Entrada Therapeutics in the 2nd quarter valued at about $72,000. Hedge funds and other institutional investors own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.